PhaseBio Pharmaceuticals: Q1 Earnings Insights

Benzinga2022-05-16

PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported its Q1 earnings results on Monday, May 16, 2022 at 06:00 AM.

Here's what investors need to know about the announcement.

Earnings

PhaseBio Pharmaceuticals beat estimated earnings by 65.15%, reporting an EPS of $-0.23 versus an estimate of $-0.66.

Revenue was up $117.00 thousand from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.31 which was followed by a 5.0% drop in the share price the next day.

Here's a look at PhaseBio Pharmaceuticals's past performance:

Quarter Q4 2021 Q3 2021 Q2 2021 Q1 2021
EPS Estimate -0.59 -0.61 -0.48 -0.69
EPS Actual -0.90 -0.66 -0.60 -0.87
Revenue Estimate 1.97M 1.07M 4.02M 30.00K
Revenue Actual 158.00K 335.00K 10.34M 0

To track all earnings releases for PhaseBio Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment